In vitro evidence for endocrine-disrupting chemical (EDC)’s inhibition of drug metabolism

index, and is mainly metabolized through UGT2B isoforms-catalyzed biotransformation reaction . In the present study, the inhibition capability of BPA towards the typical substrate of UGT2B zidovudine (AZT) was Abstract Background: Humans can be frequently exposed to Bisphenol A (BPA) via multiple sources, and babies are considered to be the most sensitive group to exposure of BPA. Aims: To investigate the inhibition potential of BPA towards human liver microsomes (HLMs)-catalyzed zidovudine (AZT) glucuronidation. Materials and Methods: In vitro HLMs incubation system was used to investigate the inhibition potential of BPA towards AZT glucuronidation. Both Dixon and Lineweaver-Burk plots were employed to determine the inhibition kinetic type, and nonlinear repression was utilized to calculate the inhibition kinetic parameters (K i ). Results: Concentration-dependent inhibition of BPA towards AZT glucuronidation was observed. Both Dixon and Lineweaver-Burk plots showed that BPA exerted competitive inhibition towards the glucuronidation of AZT, and nonlinear repression with competitive equation was used to calculate the K i value to be 3.2 μM. Conclusion : Potential BPA-AZT interaction might occur when the patients administered with AZT is also exposed to BPA.

evaluated, trying to indicate the possible influence endocrine-disrupting chemical (EDC)'s inhibition of drug metabolism.
AZT glucuronidation assays and analysis method 500 μM of AZT was used to incubate in the human liver microsomal incubation system (0.5 mg/ml of HLM, 5 mM UDPGA, 5 mM MgCl 2 , 50 mM Tris-HCl buffer (pH 7.4), 50 μg/mg protein alamethicin).The incubation time was 20 min, and the analysis of AZT glucuronidation was performed on HPLC system.The HPLC column was eluted at 1 ml/min with a mobile phase of acetonitrile:aqueous containing 0.2% formic acid (v:v=12:88).The detection wavelength was set at 267 nm.The standard curve of AZT was employed to quantify the AZT metabolite due to the lack of the standard of AZT glucuronide.

Determination of BPA's inhibition towards the glucuronidation reaction of AZT Inhibition ability of different concentrations of BPA
towards the glucuronidation of AZT was determined, and the IC 50 value was determined as previously described 10 .The reaction velocity was determined at multiple concentrations of BPA and AZT.Dixon plot (1/reaction velocity versus the concentration of BPA) and Lineweaver-Burk plot (1/reaction velocity versus 1/[the concentration of AZT]) were employed to determine the inhibition kinetic type, and nonlinear regression equation was performed using the equations for competitive inhibition (1), noncompetitive inhibition (2).
Where the items are defined as followed: V is the reaction velocity, [S] and [I] are the concentrations of substrate and inhibitor, respectively.Km value is the substrate concentration in which the velocity reached to half of the maximum velocity (Vmax) of the reaction.Ki value is the inhibition constant.

Discussion
Humans will be exposed to numerous xenobiotics everyday, such as food, drugs, herbs, and environmental pollutants.Therefore, the interaction among the compounds existed in these substances will occur, including drug-drug interaction and herb-drug interaction.All these interactions are mainly induced through affecting the pharmacokinetic behaviour, especially for the influence towards the metabolism of compounds.Many great efforts have been given to cytochrome P450 (CYP) which has been the most important DME involved in the metabolism of most of clinical drugs, and many compounds have been demonstrated to inhibit the activity of CYP isoforms.For example, the potential anti-tumor drug noscapine can inhibit the activity of CYP3A4 and CYP2C9 to explain the clinical noscapine-warfarin interaction 11 .The herbal components ginsenosides have been reported to exhibit inhibition towards the activity of several CYP isoforms 12 .Halogenated aromatic compounds (HACs) have been reported to inhibit CYP 1A2-dependent MROD activity 13 .
The important role of UDP-glucuronosyltransferases (UGTs) in the metabolic elimination of xenobiotics and endogenous substances has been drawing more and more attention in recent years 14 , and some compounds have been observed to show inhibitory potential towards UGT isoforms.For example, ketoconazole has high potential to inhibit lorazepam clearance to a clinically significant extent through affecting the glucuronidation of R-and S-Lorazepam 15 .The inhibition of ginsenosides towards several UGT isoforms have been suspected to be a potential reason for ginseng-drugs interaction 16 .
In the present study, we tried to investigate the inhibition of HLMs-catalyzed AZT glucuronidation by BPA which is an important endocrine disrupting chemical.Possible BPA-AZT interaction was indicated due to the competitive inhibition of BPA towards the glucuronidation of AZT with relatively low K i value.Additionally, some previous literatures have indicated that the addition of bovine serum albumin (BSA) in the incubation system mgiht significantly influence the in vitro inhibition parameters 17 .Therefore, different inhibition kinetic parameters might be obtained if the BSA was added in the in vitro incubation system.It should be noted that BPA can inhibit the activity of another important UGT isoform UGT1A6 when using serotonin (5-HT) and 4-methylumbelliferone (4-MU) as the probe substrates 18 .All these results indicated that exposure of BPA will affect the metabolic elimination of some clinical drugs through influencing the activity of UGT isofomrs.